• <rp id="vpc4d"></rp>

        1. <s id="vpc4d"><object id="vpc4d"><blockquote id="vpc4d"></blockquote></object></s>

          Fully Integrated Platform

          Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

          Antibody-based Immunotherapy

          ASC22,PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable,phase 2 ready.

          First/Best-in-Class Small Molecules

          ASC40, first-in-class FASN inhibitor for NASH, phase 2. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.


          ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.

          Imagine what you could do at Ascletis

          Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.

          Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.

          We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.

          赌场直营公司_网上赌场项目_亚州体育赌场-歌礼生物科技(杭州)有限公司 真人博彩五大 澳门信誉现金博彩